3.40Open3.40Pre Close0 Volume6 Open Interest12.00Strike Price0.00Turnover113.60%IV2.93%PremiumDec 20, 2024Expiry Date3.14Intrinsic Value100Multiplier19DDays to Expiry0.26Extrinsic Value100Contract SizeAmericanOptions Type-0.8534Delta0.1034Gamma2.71Leverage Ratio-0.0129Theta-0.0042Rho-2.31Eff Leverage0.0046Vega
Aurinia Pharmaceuticals Stock Discussion
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet